The clinical spectrum of Castleman's disease

Angela Dispenzieri, James Olen Armitage, Matt J. Loe, Susan M. Geyer, Jake Allred, John K. Camoriano, David M. Menke, Dennis D. Weisenburger, Kay Ristow, Ahmet Dogan, Thomas M. Habermann

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10-year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5-year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study.

Original languageEnglish (US)
Pages (from-to)997-1002
Number of pages6
JournalAmerican Journal of Hematology
Volume87
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

POEMS Syndrome
Giant Lymph Node Hyperplasia
Survival
Multi-centric Castleman's Disease

ASJC Scopus subject areas

  • Hematology

Cite this

Dispenzieri, A., Armitage, J. O., Loe, M. J., Geyer, S. M., Allred, J., Camoriano, J. K., ... Habermann, T. M. (2012). The clinical spectrum of Castleman's disease. American Journal of Hematology, 87(11), 997-1002. https://doi.org/10.1002/ajh.23291

The clinical spectrum of Castleman's disease. / Dispenzieri, Angela; Armitage, James Olen; Loe, Matt J.; Geyer, Susan M.; Allred, Jake; Camoriano, John K.; Menke, David M.; Weisenburger, Dennis D.; Ristow, Kay; Dogan, Ahmet; Habermann, Thomas M.

In: American Journal of Hematology, Vol. 87, No. 11, 01.11.2012, p. 997-1002.

Research output: Contribution to journalArticle

Dispenzieri, A, Armitage, JO, Loe, MJ, Geyer, SM, Allred, J, Camoriano, JK, Menke, DM, Weisenburger, DD, Ristow, K, Dogan, A & Habermann, TM 2012, 'The clinical spectrum of Castleman's disease', American Journal of Hematology, vol. 87, no. 11, pp. 997-1002. https://doi.org/10.1002/ajh.23291
Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK et al. The clinical spectrum of Castleman's disease. American Journal of Hematology. 2012 Nov 1;87(11):997-1002. https://doi.org/10.1002/ajh.23291
Dispenzieri, Angela ; Armitage, James Olen ; Loe, Matt J. ; Geyer, Susan M. ; Allred, Jake ; Camoriano, John K. ; Menke, David M. ; Weisenburger, Dennis D. ; Ristow, Kay ; Dogan, Ahmet ; Habermann, Thomas M. / The clinical spectrum of Castleman's disease. In: American Journal of Hematology. 2012 ; Vol. 87, No. 11. pp. 997-1002.
@article{9486e4407f8a4969877b5d123fb464d0,
title = "The clinical spectrum of Castleman's disease",
abstract = "Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32{\%} had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10-year OS was 92{\%}, 76{\%}, 59{\%}, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5-year OS): (1) unicentric CD (91{\%}); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90{\%}); (3); multicentric CD without POEMS syndrome (65{\%}); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27{\%}). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study.",
author = "Angela Dispenzieri and Armitage, {James Olen} and Loe, {Matt J.} and Geyer, {Susan M.} and Jake Allred and Camoriano, {John K.} and Menke, {David M.} and Weisenburger, {Dennis D.} and Kay Ristow and Ahmet Dogan and Habermann, {Thomas M.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1002/ajh.23291",
language = "English (US)",
volume = "87",
pages = "997--1002",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - The clinical spectrum of Castleman's disease

AU - Dispenzieri, Angela

AU - Armitage, James Olen

AU - Loe, Matt J.

AU - Geyer, Susan M.

AU - Allred, Jake

AU - Camoriano, John K.

AU - Menke, David M.

AU - Weisenburger, Dennis D.

AU - Ristow, Kay

AU - Dogan, Ahmet

AU - Habermann, Thomas M.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10-year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5-year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study.

AB - Castleman's disease (CD) is a rare, poorly understood lymphoproliferative disease. The spectrum of symptoms and course of disease are broad, but there is no large study describing the natural history of this disease. Basic clinic and laboratory data from the records of 113 patients with CD evaluated at the Mayo Clinic and University of Nebraska were abstracted. The impact of these variables on overall survival (OS) from time of diagnosis was evaluated. Sixty patients had multicentric disease. Of the patients with multicentric CD, 32% had criteria sufficient for a diagnosis of POEMS syndrome. For all patients, 2, 5, and 10-year OS was 92%, 76%, 59%, respectively. Most of the factors identified as risk factors for death on univariate analysis cosegregated with diagnostic criteria for POEMS syndrome, which supported the concept of four categories of CD, which are (along with their 5-year OS): (1) unicentric CD (91%); (2) multicentric CD associated with the osteosclerotic variant of POEMS syndrome (90%); (3); multicentric CD without POEMS syndrome (65%); and (4) multicentric CD with POEMS syndrome without osteosclerotic lesions (27%). We have demonstrated that CD represents a spectrum of disease that can be differentiated by simple prognostic factors that provide a framework for further study.

UR - http://www.scopus.com/inward/record.url?scp=84867907569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867907569&partnerID=8YFLogxK

U2 - 10.1002/ajh.23291

DO - 10.1002/ajh.23291

M3 - Article

C2 - 22791417

AN - SCOPUS:84867907569

VL - 87

SP - 997

EP - 1002

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 11

ER -